Abstract Number: 1094 • 2017 ACR/ARHP Annual Meeting
A Model for Improved Management of Fragility Fractures: Navigating the Fracture Liaison Service
Background/Purpose: Fragility fractures are associated with significant morbidity, mortality and healthcare costs, yet most fracture patients are neither evaluated nor treated for their underlying osteoporosis…Abstract Number: 1214 • 2017 ACR/ARHP Annual Meeting
Fracture Incidence and Characteristics in Young Adults Age 18 to 49 Years: A Population-Based Study
Background/Purpose: While fractures in both the elderly and pediatric populations have been extensively investigated, comparatively little attention has been given to the age-group in between.…Abstract Number: 1217 • 2017 ACR/ARHP Annual Meeting
Evaluation of Post Fracture Management in Males at a Veterans Affairs Health System
Background/Purpose: The worldwide incidence of hip fractures in men is rising, and by 2050 is projected to increase by 310%. Increased hip fracture rates may…Abstract Number: 1890 • 2017 ACR/ARHP Annual Meeting
Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed By 24 Months of Alendronate
Background/Purpose: In the ACTIVE phase III trial, postmenopausal women with osteoporosis were randomized 1:1:1 to abaloparatide (ABL; n=824), blinded placebo (PBO; n=821), or open-label teriparatide…Abstract Number: 2920 • 2017 ACR/ARHP Annual Meeting
Comparative Rates of Osteoporotic Fractures Among U.S. Medicaid Enrollees with and without Systemic Lupus Erythematosus
Background/Purpose: Fractures are potentially avoidable and highly morbid. We studied non-vertebral fracture rates among SLE patients enrolled in Medicaid, the U.S. health insurance program for…Abstract Number: 304 • 2017 ACR/ARHP Annual Meeting
Usefulness of Consecutive Doppler Ultrasound Examinations for Detecting Deep Venous Thrombosis during the Perioperative Period in Patients with Osteoporotic Fractures of the Proximal Femur
Background/Purpose: Deep venous thrombosis (DVT) can lead to a venous thromboembolism and increase the risk of a pulmonary thromboembolism (PE). PE is one of the…Abstract Number: 318 • 2017 ACR/ARHP Annual Meeting
A Randomized Alendronate-Controlled Trial of Romosozumab: Results of the Phase 3 Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk
Background/Purpose: The bone forming agent romosozumab (Romo) was previously shown to reduce vertebral and clinical fractures in postmenopausal women with osteoporosis. Here we report the…Abstract Number: 320 • 2017 ACR/ARHP Annual Meeting
Teriparatide Compared with Risedronate and the Risk of Clinical Vertebral Fractures: 2-Year Results of a Randomized, Double-Dummy Clinical Trial
Background/Purpose: The VERO trial was an active-controlled fracture endpoint clinical trial that recruited postmenopausal women with low bone mass and prevalent vertebral fractures (VFx). We…Abstract Number: 21 • 2016 ACR/ARHP Annual Meeting
Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Background/Purpose: Rheumatoid arthritis (RA) is a well-known risk factor for osteoporosis and hip fracture. Recent studies suggest RA patients fracture at a younger age and…Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting
Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting
The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab
Background/Purpose: Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture. Although osteoporosis therapy decreases fracture risk, fractures while on…Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting
Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
Background/Purpose: Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture. The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…Abstract Number: 345 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: To explore the relationship of anti-CCP levels with BMD or fragility fracture in patients with RA Methods: This is a prospective cross sectional study.…Abstract Number: 895 • 2016 ACR/ARHP Annual Meeting
Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease associated with older age and long term use of glucocorticoids. As such a high incidence of osteoporosis…Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting
Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
Background/Purpose: Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…